“the big pharmaceutical developers, the the big diagnostics companies with oncologists. And it really made us aware of of a couple of different gaps in the market. And so we looked at the the technologies that we'd been developing and we realized that actually we had solutions to some really fundamental problems in ah in our space. And so we took the decision at the time to start up a couple of small projects in the company and then ultimately to split the company into three.”